FDA approves biosimilar version of bevacizumab

By Dr Deepu

FDA  has approved a “biosimilar version of” Avastin (bevacizumab). “Like the reference product, the biosimilar bevacizumab is approved for use in several types of cancer, including metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, cervical cancer, and glioblastoma.” “Like Avastin, the labeling for” the new product, has a boxed warning about an increased risk of: holes in the stomach and intestines; surgery and wound healing complications; and severe or fatal pulmonary, gastrointestinal, central nervous system and vaginal bleeding.”